Wolfgang Feneberg

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Ludwig Kappos, Amit Bar‐Or, Bruce Cree et al. · The Lancet · 2018 · 925 citations

Medicine, Neurology, Pharmacology +9

Characterizing absolute lymphocyte count profiles in dimethyl fumarate–treated patients with MS

Robert J. Fox, Andrew Chan, Ralf Gold et al. · Neurology Clinical Practice · 2016 · 104 citations · Full text

Life Sciences, Immunology, Pharmacology +14

CSF and serum levels of soluble interleukin-6 receptors (sIL-6R and sgp130), but not of interleukin-6 are altered in multiple sclerosis1Part of this work was presented in abstract form at the Twenty-Seventh Annual Meeting of the Society for Neuroscience, October 25–30, 1997, New Orleans, LA, USA.1

Frank Padberg, Wolfgang Feneberg, Stephan Schmidt et al. · Journal of Neuroimmunology · 1999 · 87 citations

Life Sciences, Neurology, Neuroscience +9

Interferon beta but not glatiramer acetate therapy aggravates headaches in MS

W. Pöllmann, Lutz-Peter Erasmus, Wolfgang Feneberg et al. · Neurology · 2002 · 81 citations

Engineering, Environmental Engineering, Environmental Remediation +15

Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study

David H. Miller, Robert J. Fox, J. Theodore Phillips et al. · Neurology · 2015 · 65 citations · Full text

Medicine, Neurology, Pharmacotherapy +16